Report of Foreign Issuer (6-k)
July 18 2017 - 9:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
July 18, 2017
001-36686
(Commission file number)
Forward Pharma A/S
(Translation of registrant’s name
into English)
Østergade 24A, 1st Floor
1100 Copenhagen K, Denmark
(Address of principal executive office)
________________________________________
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes [ ] No [ X ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes [ ] No [ X ]
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934. Yes [ ] No [ X ]
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): N/A
Item 1. Issuance of Press Release
On July 18, 2017, Forward Pharma A/S (the “Company”)
issued a press release announcing plans to return to its shareholders EUR 19.45 per share, amounting to a total of EUR 917.7 million.
The return of capital will be accomplished via a capital reduction (the “capital reduction”), which will be contingent
upon receipt of shareholder approval. The Company will hold an extraordinary general meeting on August 2, 2017 to seek shareholder
approval for the capital reduction.
The Company has filed as exhibits to this Form 6-K a press release
dated July 18, 2017, announcing the capital reduction, and the Notice to Convene Extraordinary General Meeting and accompanying
documentation.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
Date: July 18, 2017
|
|
|
|
Forward Pharma A/S
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Claus Bo Svendsen
|
|
|
|
|
|
|
Name: Claus Bo Svendsen
|
|
|
|
|
|
|
Title: Chief Executive Officer
|
EXHIBIT INDEX
|
99.1
|
Press Release
dated July 18, 2017
|
|
99.2
|
Notice to convene the extraordinary general meeting, including the agenda and the complete proposals
|
|
99.3
|
Proxy and voting
by correspondence form
|
|
99.4
|
Request for admission
card form
|
|
99.5
|
Share capital
and voting rights overview
|
|
99.6
|
Annual Report
2016 for the company
|
|
99.7
|
Articles of Association of the company marked with the proposed amendments against the company’s current Articles of
Association of 3 May 2017
|
|
99.8
|
Report of the Board of Directors on events of significance to the company’s position that have taken place since the
preparation of the Annual Report 2016
|
|
99.9
|
Statement from the independent auditor on the Report of the Board of Directors
|
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Apr 2023 to Apr 2024